Condition: Systemic Lupus Erythematosus (With and Without Nephritis) · Idiopathic Inflammatory Myopathy · Systemic Sclerosis · Sponsor: Allogene Therapeutics
This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune diseases: systemic lupus erythematosus (SLE) with and without renal involvement, idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc).The purpose of this trial is to evaluate the safety and tolerability of ALLO-329, an allogeneic anti-CD19, anti-CD70 dual chimeric antigen receptor (CAR) T cell therapy, in adults with autoimmune disorders, provide initial evidence of biological activity and clinical response to the treatment and determine the recommended Phase 2 regimen (RP2R).
This description comes directly from the study's public registry record.
Allogene Therapeutics, Inc. · +1 415-604-5696 · clinicaltrials@allogene.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Phoenix, Arizona, United States | Recruiting |
| Loma Linda University Medical Center | Loma Linda, California, United States | Recruiting |
| University of Colorado Denver | Aurora, Colorado, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| The University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| Norton Cancer Institute, St. Matthews Campus | Louisville, Kentucky, United States | Recruiting |
| Astera Cancer Care | East Brunswick, New Jersey, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
| Medical University of South Carolina | Charleston, South Carolina, United States | Recruiting |
| Prisma Health | Greenville, South Carolina, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07085104